TOKYO, Oct 20 (Reuters) - Pfizer Inc PFE.N and BioNTech SE announced on Tuesday the start in Japan of combined Phase I and Phase II clinical trials of their mRNA vaccine candidate against the coronavirus.
The study will recruit 160 people aged 20 to 85, the companies said in a statement. They had earlier agreed to supply Japan with 120 million doses of their experimental coronavirus vaccine in the first half of 2021.
(Reporting by Rocky Swift; Editing by Clarence Fernandez)
In This StoryPFE
Latest Markets Videos
- White House says Walmart, FedEx, UPS to work 24/7 to ease supply bottlenecks for holiday season
- Chinese online brokers Futu and UP Fintech face regulatory risks - People's Daily website
- September, Third Quarter 2021 Review and Outlook
- PRECIOUS-Gold eases as inflation data fans policy tightening bets